Hipertrófiás kardiomiopátia: vizsgálatok itt: Ausztria
6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
- Where
- Graz
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Imbria Pharmaceuticals Inc.
See details and how to join2024-515125-28-00 - 2. fázisTaking peopleA Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Where
- Graz
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- Imbria Pharmaceuticals, Inc.
See details and how to joinNCT07023614 - No phaseTaking peopleA Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- Where
- Braunau am Inn, Graz, Innsbruck, Klagenfurt, Linz, Sankt Pölten, Vienna
- Életkor
- 18 év and over
- People
- 1700 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT05489705 - 4. fázisTaking peopleHYDrochlorothiazidE compared to valsartan to treat arterial hypertension in patients with Hypertrophic obstructive CardioMyopathy – the HYDE-HCM Trial
- Where
- Graz, Linz, St. Pölten, Vienna, Wien
- Életkor
- 18 év and over
- People
- 40
- Run by
- Medical University Of Graz
See details and how to join2024-520086-31-00 - No phaseTaking peopleAustrian Hypertrophic Cardiomyopathy Registry
- Where
- Braunau am Inn, Graz, Innsbruck, Linz, Salzburg, Sankt Johann in Tirol, Sankt Pölten, Schwarzach im Pongau, Vienna, Wels-Grieskirchen, Wiener Neustadt
- Életkor
- 18 év and over
- People
- 1000
- Run by
- Medical University of Graz
See details and how to joinNCT06368518 - No phaseTaking peopleMyocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 20
- Run by
- Medical University of Vienna
See details and how to joinNCT07150299